Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + nivolumab + chemotherapy versus nivolumab + chemotherapy in first-line LAG-3-positive gastric or gastroesophageal junction adenocarcinoma
2018-001069-18Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab, nivolumab, oxaliplatin, capecitabine, fluorouracil in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Bristol Myers Squibb. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2018-001069-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001069-18.